US 11,806,392 B2
Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein A
David E. Briles, Birmingham, AL (US); Hiroshi Kiyono, Tokyo (JP); Robert Kneller, Tokyo (JP); Reshmi Mukerji, Birmingham, AL (US); Kristopher Genschmer, Irondale, AL (US); and Yoshikazu Yuki, Tokyo (JP)
Assigned to The UAB Research Foundation, Birmingham, AL (US); and The University of Tokyo, Tokyo (JP)
Appl. No. 16/463,364
Filed by The UAB Research Foundation, Birmingham, AL (US); and The University of Tokyo, Tokyo (JP)
PCT Filed Dec. 1, 2017, PCT No. PCT/US2017/064347
§ 371(c)(1), (2) Date May 22, 2019,
PCT Pub. No. WO2018/102774, PCT Pub. Date Jun. 7, 2018.
Claims priority of provisional application 62/429,782, filed on Dec. 3, 2016.
Prior Publication US 2019/0351043 A1, Nov. 21, 2019
Int. Cl. A61K 39/09 (2006.01); A61P 31/04 (2006.01); C07K 14/315 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/092 (2013.01) [A61P 31/04 (2018.01); C07K 14/3156 (2013.01); A61K 2039/54 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55583 (2013.01)] 7 Claims
 
1. A composition comprising an immunologically active amount of at least two recombinant aHD-PRD constructs, each construct consisting of a portion of an alpha helical domain (aHD) and a portion of a proline rich domain (PRD) of a Streptococcus pneumoniae pneumococcal surface protein A (PspA), wherein each aHD and PRD portion is connected by a peptide bond, a chemical moiety, or a peptide linker, and the composition comprises at least one pharmaceutically acceptable excipient;
wherein the aHD and the PRD are each selected according to the following steps (a) and (b):
(a) selecting a first aHD from clade 1 of PspA family 1, wherein said aHD 1s selected from SEQ ID NO:66 SEQ ID NO:75, SEQ ID NO:78, or SEQ ID NO:79, and selecting a first PRD from a first PRD Group, and
(b) selecting a second aHD from clade 3, clade 4, or clade 5 of PspA family 2, wherein said aHD is selected from SEQ ID NO:33, SEQ ID 42, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, or SEQ ID NO:81, and selecting a second PRD from a second PRD Group, wherein said first and said second PRD Groups are each selected from:
PRD Group 1 consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:128;
PRD Group 2 consisting of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, and SEQ ID NO:104; or
PRD Group 3 consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:95, SEQ ID NO:114, SEQ ID NO:125, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO: 142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, and SEQ ID NO:157; wherein said composition is antigenic or immunogenic; and wherein said composition does not occur in nature.